Friday, January 14, 2022 9:15:11 PM
Biosect,
In the case of Gleevec I believe a trial that was supposed to go to several hundred was stopped with under 80 because it was clearly saving lives. While the DSMB's primary function may be safety, I believe they can advocate to end a trial at any time they're convinced a product shouldn't require further testing to be approved. I can't say how often the regulators actually accept their recommendation, and of course no documents are ever revealed of such recommendations unless action is taken that's based on what they're recommending.
Clearly I'm advocating that the regulators use their own eyes to see what's happening in the clinic and not rely on only the statistics generated in the trial, especially when the DSMB recommends doing so. No one should need to know more than the statistics on the Top 100 or roughly 300 who received the vaccine to know that this should be approved immediately.
I believe the fact that in the U.K. Dr. Ashkan is free to offer DCVax-L to patients with all forms of solid cancers under compassionate use is amazing. I've heard of many people attempting to get drugs under compassionate use, in some cases the company supported it, in other cases they didn't. The point is, they never solicited it. Dr. Ashkan appears to be openly saying it's available, come and get it if you can afford it under provisions of compassionate use. By the time we have approval he may have substantial evidence of it's use in other cancers even if it's only six months or so under treatment with it. A substantial anecdotal database should be established in just a few years.
I guess that what I'm saying is, the regulators can make the choice to greatly expedite approvals when they so choose. Clearly Covid-19 has been handled in this way, much the same could be done with deadly diseases like cancer. An EUA could have been issued back in 2018 based on Top 100 alone, that could have permitted it's use covered by insurance until sufficient data was gathered for full approval, if it can be done for Covid-19, why not cancer. I know we don't have hundreds of thousands dying of GBM annually, but for those who have it, it's far deadlier than Covid-19.
Gary
In the case of Gleevec I believe a trial that was supposed to go to several hundred was stopped with under 80 because it was clearly saving lives. While the DSMB's primary function may be safety, I believe they can advocate to end a trial at any time they're convinced a product shouldn't require further testing to be approved. I can't say how often the regulators actually accept their recommendation, and of course no documents are ever revealed of such recommendations unless action is taken that's based on what they're recommending.
Clearly I'm advocating that the regulators use their own eyes to see what's happening in the clinic and not rely on only the statistics generated in the trial, especially when the DSMB recommends doing so. No one should need to know more than the statistics on the Top 100 or roughly 300 who received the vaccine to know that this should be approved immediately.
I believe the fact that in the U.K. Dr. Ashkan is free to offer DCVax-L to patients with all forms of solid cancers under compassionate use is amazing. I've heard of many people attempting to get drugs under compassionate use, in some cases the company supported it, in other cases they didn't. The point is, they never solicited it. Dr. Ashkan appears to be openly saying it's available, come and get it if you can afford it under provisions of compassionate use. By the time we have approval he may have substantial evidence of it's use in other cancers even if it's only six months or so under treatment with it. A substantial anecdotal database should be established in just a few years.
I guess that what I'm saying is, the regulators can make the choice to greatly expedite approvals when they so choose. Clearly Covid-19 has been handled in this way, much the same could be done with deadly diseases like cancer. An EUA could have been issued back in 2018 based on Top 100 alone, that could have permitted it's use covered by insurance until sufficient data was gathered for full approval, if it can be done for Covid-19, why not cancer. I know we don't have hundreds of thousands dying of GBM annually, but for those who have it, it's far deadlier than Covid-19.
Gary
Recent NWBO News
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 11/26/2025 05:15:34 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
